Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
NCT ID: NCT02462499
Last Updated: 2016-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
28 participants
INTERVENTIONAL
2014-06-30
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
NCT02215330
Eplerenone for the Treatment of Central Serous Chorioretinopathy
NCT01990677
Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
NCT02151695
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
NCT05959304
A New Treatment of Retinitis Pigmentosa
NCT03998384
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
Inspra (eplerenone)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inspra (eplerenone)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
* Pregnant women or who are actively trying to conceive.
* Additional eye disease affecting the macula or posterior retina.
* Creatinine clearance \< 50 ml/min
* Hyperkalemia \> 5 mmol/l
* Serum creatinine \> 2 mg/dl in men or \> 1.8 mg/dl in women
* Treatment with potassium sparing agents or potassium
* Treatment with any other drugs known to cause interaction with eplerenone
* Microalbuminuria in patients with type 2 diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Semmelweis University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Ecsedy
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Semmelweis University, Department of Ophthalmology
Budapest, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSCR 104/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.